Ovid Therapeutics (OVID) Non-Current Assets (2016 - 2026)

Ovid Therapeutics has reported Non-Current Assets for 11 years, with the latest figure at $65.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 83.26% year-over-year to $65.5 million; the trailing twelve-month figure through Mar 2026 stood at $212.4 million (up 45.5% YoY), and the FY2025 full-year result was $76.6 million, up 111.35% from the prior year.
• Non-Current Assets for Q1 2026 stood at $65.5 million, down from $76.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $76.6 million in Q4 2025, with the low at $21.0 million in Q1 2022.
• Historically, Non-Current Assets has averaged $36.1 million across 5 years, with a median of $35.0 million in 2025.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 2546.02% — and 2025, when it dropped 7.05%.
• Ovid Therapeutics' Non-Current Assets stood at $23.9 million in 2022, then soared by 44.14% to $34.4 million in 2023, then advanced by 5.22% to $36.2 million in 2024, then surged by 111.35% to $76.6 million in 2025, then decreased by 14.48% to $65.5 million in 2026.
• The last three Non-Current Assets figures came in at $65.5 million (Q1 2026), $76.6 million (Q4 2025), and $35.0 million (Q3 2025), per Business Quant data.